Authors  Infection  Study Characteristics  Observations  Unique Considerations
Chen et al. 10  HBV  Retrospective analysis of hospitalized patients with COVID‐19 in a single center in Wuhan, China  12.2% (15/123) of patients were HBV infected
A higher percentage with comorbid HBV developed a severe outcome (46.7% versus 24.1%)
Total bilirubin level was higher in patients with comorbid HBV
Patients with comorbid HBV had a higher mortality rate (13.3% versus 2.8%)  Heterogeneous data on the prevalence of HBV infection in COVID‐19 and on the interaction between HBV and COVID‐19
Risk for HBV reactivation with some experimental COVID‐19 therapies (tocilizumab, corticosteroids)
Some investigational COVID‐19 medications may be contraindicated in HBV‐infected patients with decompensated cirrhosis
Zha et al. 11  Observational study investigating the efficacy of corticosteroid treatment in hospitalized patients with COVID‐19 in China  6.5% (2/31) of patients were HBV infected
Association found between HBV infection and prolonged SARS‐CoV‐2 clearance
Richardson et al. 8  Case series of hospitalized patients with COVID‐19 in 12 hospitals in the New York City metro area  0.1% (8/5700) of patients were HBV infected
Guan et al. 9  Retrospective multicenter analysis of hospitalized patients with COVID‐19 in China  2.1% (23/1099) of patients were HBV infected
HBV‐infected individuals represented 2.4% of nonsevere cases and 0.6% of severe cases
Richardson et al. 8  HCV  Case series of hospitalized patients with COVID‐19 in 12 hospitals in the New York City metro area  <0.1% (3/5700) of patients were HCV infected  Low incidence of HCV in hospitalized patients with COVID‐19
No studies to date have reported the effect of HCV on COVID‐19 outcomes
Some investigational COVID‐19 medications may be contraindicated in patients with HCV‐related decompensated cirrhosis
Blanco et al. 12  HIV  Clinical case series of 5 hospitalized COVID‐19 patients in a single center in Spain  0.92% of patients were HIV infected
0 died, 2 were admitted to the ICU (1 remained in the ICU at publication)
ART regimens adapted to protease inhibitor in all patients  Low incidence of hospitalized patients with COVID‐19 and HIV
ART may need to be adapted
Although no studies have investigated COVID‐19 in PWIDs, that population has risk factors for severe disease course, including weaker immune system, cardiac pathology, and renal insufficiency
Heterogeneous data on time to antibody response and time to clinical improvement
Zhu et al. 13  Case study in China in a HIV/SARS‐CoV‐2 co‐infected patient  Comorbid diabetes and heavy smoker
Antibody/antigen test gave positive HIV results (no previous ART)
Chen et al. 15  Case study in China in a patient co‐infected with HIV/SARS‐CoV‐2  Nonsevere COVID‐19 pneumonia
Had ongoing ART HIV treatment (tenofovir, lamivudine, efavirenz)
After COVID‐19 diagnosis, given lopinavir/ritonavir
Shortened disease course and quick resolution of pulmonary lesions
Aydin et al. 14  Case series of 4 patients co‐infected with HIV/SARS‐CoV‐2 in Turkey  In limited cases, study highlighted that COVID‐19 infection improved in cases using regular ART with viral suppression
One patient died of sudden cardiac arrest
Resolution of radiological findings and time to antibody formation were similar to HIV‐uninfected patients with COVID‐19
Zhao et al. 16  HCV+HIV  Case study in China of HIV/HCV co‐infected patient with COVID‐19  Negative SARS‐CoV‐2 RNA test and delayed antibody response
Was taking anti‐HIV ART